{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:29:30Z","timestamp":1784305770004,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s40801-022-00349-9","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T07:02:43Z","timestamp":1673420563000},"page":"207-213","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study"],"prefix":"10.1007","volume":"10","author":[{"given":"Charlotte","family":"Bellier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Gladieff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Le Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Berton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Bonnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Suau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-C\u00e9line","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oph\u00e9lie","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Lahouegue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Freyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Floquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kfoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,11]]},"reference":[{"key":"349_CR1","unstructured":"Institut National du Cancer. Recommandations professionnelles: cancer de l\u2019ovaire. Traitement chirurgical. Juin 2019. Available from: www.e-cancer.fr. [Accessed 19 Dec 2022]."},{"issue":"1","key":"349_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S1470-2045(13)70546-1","volume":"15","author":"R De Angelis","year":"2014","unstructured":"De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999\u20132007 by country and age: results of EUROCARE-5: a population-based study. Lancet Oncol. 2014;15(1):23\u201334. https:\/\/doi.org\/10.1016\/S1470-2045(13)70546-1.","journal-title":"Lancet Oncol"},{"issue":"6","key":"349_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/annonc\/mdt333","volume":"24","author":"JA Ledermann","year":"2013","unstructured":"Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(6):24\u201332. https:\/\/doi.org\/10.1093\/annonc\/mdt333.","journal-title":"Ann Oncol"},{"issue":"4","key":"349_CR4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1023\/A:1008256431090","volume":"8","author":"HE Lambert","year":"1997","unstructured":"Lambert HE, Rustin GJ, Gregory WM, Nelstrop AE. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma: a North Thames Ovary Group study. Ann Oncol. 1997;8(4):327\u201333.","journal-title":"Ann Oncol"},{"issue":"9","key":"349_CR5","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","volume":"27","author":"MA Bookman","year":"2009","unstructured":"Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27(9):1419\u201325.","journal-title":"J Clin Oncol"},{"issue":"7","key":"349_CR6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2217\/fon-2019-0042","volume":"16","author":"CE Haunschild","year":"2020","unstructured":"Haunschild CE, Tewari KS. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer. Future Oncol. 2020;16(7):225\u201346.","journal-title":"Future Oncol"},{"issue":"12","key":"349_CR7","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.2147\/OTT.S155425","volume":"8","author":"C Marchetti","year":"2019","unstructured":"Marchetti C, Muzii L, Romito A, Benedetti PP. First-line treatment of women with advanced ovarian cancer: focus on bevacizumab. Onco Targets Ther. 2019;8(12):1095\u2013103.","journal-title":"Onco Targets Ther"},{"issue":"3","key":"349_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/jncics\/pkaa026","volume":"4","author":"O Colomban","year":"2020","unstructured":"Colomban O, Tod M, Peron J, Perren TJ, Leary A, Cook AD, et al. Bevacizumab for newly diagnosed ovarian cancers: best candidates among high-risk disease patients (ICON-7). JNCI Cancer Spectr. 2020;4(3):26. https:\/\/doi.org\/10.1093\/jncics\/pkaa026.","journal-title":"JNCI Cancer Spectr."},{"issue":"1","key":"349_CR9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ygyno.2020.07.022","volume":"159","author":"D Lorusso","year":"2020","unstructured":"Lorusso D, Marchetti C, Conte C, Giudice E, Bolomini G, Vertechy L, et al. Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: a large, retrospective, multicenter case-control study. Gynecol Oncol. 2020;159(1):95\u2013100.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"349_CR10","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","volume":"60","author":"MJ O'Connor","year":"2015","unstructured":"O\u2019Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60(4):547\u201360.","journal-title":"Mol Cell"},{"issue":"9","key":"349_CR11","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274\u201384. https:\/\/doi.org\/10.1016\/S1470-2045(17)30469-2.","journal-title":"Lancet Oncol"},{"issue":"15","key":"349_CR12","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"J Ledermann","year":"2012","unstructured":"Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382\u201392.","journal-title":"N Engl J Med"},{"issue":"26","key":"349_CR13","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495\u2013505.","journal-title":"N Engl J Med"},{"issue":"12","key":"349_CR14","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","volume":"22","author":"S Banerjee","year":"2021","unstructured":"Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1721\u201331. https:\/\/doi.org\/10.1016\/S1470-2045(21)00531-3.","journal-title":"Lancet Oncol"},{"key":"349_CR15","doi-asserted-by":"crossref","unstructured":"Bellier C, Gladieff L, Le Du F, Garnier C, Berton D, Bonnard C, et al. First real-life data on olaparib in 1st line maintenance BRCA1\/2 mutated epithelial ovarian cancer in France: descriptive analysis of 201 patients enrolled in the Cohort Temporary Authorization for Use (ATUc). Presented at the Virtual European Society for Medical Oncology Congress; 2020.","DOI":"10.1016\/j.annonc.2020.08.966"},{"issue":"8","key":"349_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/annonc\/mdx443","volume":"28","author":"EA Eisenhauer","year":"2017","unstructured":"Eisenhauer EA. Real-world evidence in the treatment of ovarian cancer. Ann Oncol. 2017;28(8):61\u20135. https:\/\/doi.org\/10.1093\/annonc\/mdx443.","journal-title":"Ann Oncol"},{"issue":"1","key":"349_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ygyno.2019.10.023","volume":"156","author":"SC Cecere","year":"2020","unstructured":"Cecere SC, Giannone G, Salutari V, Arenare L, Lorusso D, Ronzino G, et al. Olaparib as maintenance therapy in patients with BRCA 1\u20132 mutated recurrent platinum sensitive ovarian cancer: real world data and post progression outcome. Gynecol Oncol. 2020;156(1):38\u201344. https:\/\/doi.org\/10.1016\/j.ygyno.2019.10.023.","journal-title":"Gynecol Oncol"},{"issue":"10","key":"349_CR18","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1080\/14737140.2021.1941890","volume":"21","author":"I Romero","year":"2021","unstructured":"Romero I, L\u00f3pez-Guerrero JA, Pignata S. Real-world experience with trabectedin for the treatment of recurrent ovarian cancer. Expert Rev Anticancer Ther. 2021;21(10):1089\u201395. https:\/\/doi.org\/10.1080\/14737140.2021.1941890.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"12","key":"349_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.711813","volume":"20","author":"D Berton","year":"2021","unstructured":"Berton D, Floquet A, Lescaut W, Baron G, Kaminsky MC, Toussaint P, et al. Real-world experience of bevacizumab as first-line treatment for ovarian cancer: the GINECO ENCOURAGE cohort of 468 French patients. Front Pharmacol. 2021;20(12): 711813.","journal-title":"Front Pharmacol"},{"key":"349_CR20","first-page":"2201549","volume":"2","author":"P DiSilvestro","year":"2022","unstructured":"DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial. J Clin Oncol. 2022;2:2201549.","journal-title":"J Clin Oncol"},{"issue":"5","key":"349_CR21","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S1470-2045(21)00098-X","volume":"22","author":"M Friedlander","year":"2021","unstructured":"Friedlander M, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, et al. Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. Lancet Oncol. 2021;22(5):632\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(21)00098-X.","journal-title":"Lancet Oncol"},{"issue":"5","key":"349_CR22","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","volume":"22","author":"A Poveda","year":"2021","unstructured":"Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(5):620\u201331. https:\/\/doi.org\/10.1016\/S1470-2045(21)00073-5.","journal-title":"Lancet Oncol"},{"issue":"11","key":"349_CR23","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","volume":"17","author":"JA Ledermann","year":"2016","unstructured":"Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016;17(11):1579\u201389. https:\/\/doi.org\/10.1016\/S1470-2045(16)30376-X.","journal-title":"Lancet Oncol"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-022-00349-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-022-00349-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-022-00349-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T04:20:58Z","timestamp":1685593258000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-022-00349-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,11]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["349"],"URL":"https:\/\/doi.org\/10.1007\/s40801-022-00349-9","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,11]]},"assertion":[{"value":"11 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The work was funded by AstraZeneca France\u00a0(part of an alliance between AstraZeneca and Merck Sharp & Dohme (MSD)).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"CB, DB and CF declare no conflicts of interest. LG declares honoraria and consulting\/advisory board work for AstraZeneca. FL declares honoraria for consulting or advisory board work for Daiichi Sankyo, Lilly, Seagen, Novartis, Pfizer, Roche and Sandoz and travel fees from Daiichi Sankyo, Lilly, Novartis, Pfizer and Pierre Fabre and serves as a speaker for Amgen, Lilly, Novartis and Pierre Fabre. GF declares honoraria and advisory board work for AstraZeneca, BMS, Clovis Oncology, GSK, Lilly, MSD, Novartis and Pfizer. AF declares honoraria and congress and presentation work for AstraZeneca, GSK and Clovis Oncology. MK declares honoraria as a speaker for AstraZeneca and consultancy work for GSK.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable. The ATUc programme is not a clinical trial and thus does not require ethics\u00a0approval.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable. The ATUc programme is not a clinical trial and therefore patient consent was not required. The patients did receive a patient information leaflet.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The ATUc programme is not a clinical trial. Therefore, there is no study conception, design or material preparation. However all authors contributed to the data collection and analysis and writing of the article and the current version is approved by all authors.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}